trending Market Intelligence /marketintelligence/en/news-insights/trending/dqtyf11osnpcgzi15aeana2 content esgSubNav
In This List

Checkpoint's lung cancer therapy shows anti-tumor activity in early-stage trial

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Checkpoint's lung cancer therapy shows anti-tumor activity in early-stage trial

Checkpoint Therapeutics, Inc. said its lung cancer drug was well-tolerated and demonstrated anti-tumor activity in an early stage trial.

The phase 1/2 trial is evaluating CK-101, also known as RX518, in 19 patients with non-small cell lung cancer, the most common type of lung cancer.

Anti-tumor activity was particularly observed in patients having a mutation in the epidermal growth factor receptor, or EGFR, protein who had never undergone treatment before. Six out of these eight patients saw a reduction in tumor size but did not see their disease go away completely.

In six patients whose disease had spread to the brain, three patients saw a reduction in their cancer. A higher response rate was seen in patients who had a larger concentration of the drug in their bodies, with six out of 11 patients seeing tumor size reduction.

The company said there were no dose-limiting toxicities or treatment-related serious side effects.

Checkpoint said in a Sept. 6 news release that it plans to begin a phase 3 trial in EGFR mutation-positive non-small cell lung cancer patients who have not had prior treatment in 2019.